Critical Care Reviews Newsletter

Welcome to the 585th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials on inhaled prostacyclin therapy in the acute respiratory distress syndrome & fluid balance control in critically ill patients; systematic reviews and meta analyses on the association between neuromuscular blocking agents and the development of intensive care unit-acquired weakness & the effects of remdesivir in patients hospitalised with COVID-19; and observational studies on plasma neurofilament light chain protein as a predictor of neurological outcome after cardiac arrest & myoclonus in comatose patients with electrographic status epilepticus after cardiac arrest.

There is also a consensus report on sepsis-associated acute kidney injury; narrative reviews on external ventricular drainage & ICU nutrition; editorials on the art of the null hypothesis & the hemodynamic impact of prone positioning; and commentaries on early nutrition prescription in critically ill patients & antifungal management in ICU.

If you only have time to read one review article this week, try this one on whether artificial intelligence can help for scientific writing.

Critical Care Reviews Meeting 2023

This week we announced that the TEAM and PILOT trials were to be presented at CCR23 by their chief investigators, Profs Carol Hodgson and Matthew Semler, respectively. TEAM evaluated early active mobilisation during mechanical ventilation in the ICU, while PILOT investigated optimum oxygen saturation targets in critically ill patients receiving mechanical ventilation.

They join CLOVERS, comparing early restrictive with liberal fluid management for sepsis-induced hypotension; AID-ICU, investigating haloperidol for delirium in the ICU; DEVICE, comparing video with direct laryngoscopy for emergency intubation in the critically ill; and the UK REBOA trial, the first randomised trial evaluating REBOA in trauma patients with uncontrolled torso haemorrhage. If you're planning on attending CCR23, don't be slow to book either the meeting or your accommodation, or you'll miss out!

Support CCR

You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.